Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Globus MedicalGMED +0.61%97 14-Day RSI is 62.33 as of Aug. 13, 2026. GuruFocus rates GMED with a GF Score™ of 97/100 and a GF Value™ of $96.74 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 867 Medical Devices & Instruments companies, Globus Medical ranks worse than 77.85% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-13), Globus Medical's 14-Day RSI is 62.33.
The industry rank for Globus Medical's 14-Day RSI or its related term are showing as below:
GMED's 14-Day RSI is ranked worse than 77.85% of 867
companies
in the Medical Devices & Instruments industry
Industry Median: 52.79
vs GMED: 62.33
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Globus Medical 14-Day RSI Related Terms
GMED vs PODD, BRKR, GKOS: 14-Day RSI Comparison
For the Medical Devices subindustry, Globus Medical's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Globus Medical 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Globus Medical's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Globus Medical (GMED) has a 14-Day RSI of 62.33 as of Aug. 13, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Globus Medical and its competitors. According to the industry distribution chart, Globus Medical ranks #675 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 77.9%.
Is Globus Medical's 14-Day RSI too high?
Globus Medical's current 14-Day RSI is 62.33. The Medical Devices & Instruments industry median 14-Day RSI is 52.79. Globus Medical's value of 62.33 is 18.1% above this industry median. Based on the distribution chart, Globus Medical ranks #675 out of 867 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Globus Medical has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's 14-Day RSI compare to PODD and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Globus Medical ranks #675 out of 867 companies for 14-Day RSI. This places Globus Medical in the lower half of its industry. The industry median 14-Day RSI is 52.79. Globus Medical's value of 62.33 is 18.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 52.79, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Globus Medical's current 14-Day RSI of 62.33 is 18.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Globus Medical and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 52.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Globus Medical's current 14-Day RSI is 62.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (GMED) is currently considered Modestly Undervalued. The stock's GF Value™ is $96.74, compared to a current price of $85.67 — trading 11.4% below its estimated fair value. The current 14-Day RSI is 62.33 and 18.1% above the Medical Devices & Instruments industry median of 52.79. Globus Medical's overall GF Score™ is 97/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Globus Medical (GMED), the current 14-Day RSI is 62.33 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Globus Medical (GMED) Overvalued in 2026?
Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued.
The current stock price of $85.67 is trading 11.4% below its estimated GF Value™ of $96.74.
GuruFocus considers Globus Medical to be Modestly Undervalued.
Key valuation signals for GMED:
14-Day RSI: 62.33
GF Value™: $96.74 vs. price of $85.67 (11.4% below fair value)
Industry Position: 18.1% above the Medical Devices & Instruments median (#675 of 867)
No single metric tells the full story. See the GMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
97GF Score
Get the complete analysis for GMED
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GMED has been successfully added to your 
